Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06658093 · ClinicalTrials.gov registry record · Early Phase 1
RESTOR: PK/PD mTORi Inhibition in Older Adults
A Early Phase 1 study of Aging, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 194
- Enrollment target
- 1
- Study location
NCT06658093 is a Early Phase 1 study of Aging that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 194 participants, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06658093, a Early Phase 1 study of Aging, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 194 participants
- Enrollment target
- 1
- Study location
Study Summary
As people get older, there are changes in their cells and tissues that may affect their ability to function. This can lead to increased death and age-associated disorders, like heart disease, cancer, and Alzheimer's disease. Studies in animal models have been able to identify drugs that slow the aging process, leading to a longer, healthier life. This study is focused on one such family of drugs, called mTOR inhibitors, and the investigators' goal is to test two of these drugs, Rapamycin (Sirolimus) and Everolimus (Afinitor), in healthy older adults to find a dose and dose timing that can be used to safely inhibit mTOR to the levels seen in young healthy persons. The investigators expect that the dose that works well in women may differ from the one that is best in men, so it is important to include both sexes in this research.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Everolimus
- DRUG Rapamycin
Study Locations (1)
Texas
- The University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2025-08-13 |
| Est. Completion | 2028-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06658093
The ClinicalTrials.gov registry entry for NCT06658093 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (91% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Aging appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06658093 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06658093 about?
NCT06658093 is a clinical study titled "RESTOR: PK/PD mTORi Inhibition in Older Adults". As people get older, there are changes in their cells and tissues that may affect their ability to function. This can lead to increased death and age-associated disorders, like heart disease, cancer, and Alzheimer's disease. Studies in animal models have been able to identify drugs that slow the agi...
What is the current status of trial NCT06658093?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 194 participants. The study started on 2025-08-13. Estimated completion is 2028-07.
What conditions does trial NCT06658093 study?
This clinical trial studies the following conditions: Aging.
What interventions are being tested in trial NCT06658093?
The interventions under investigation include: Placebo (OTHER), Everolimus (DRUG), Rapamycin (DRUG).
Who is sponsoring clinical trial NCT06658093?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06658093 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gene Expression Changes In Young and Geriatric Skin
RECRUITING · Early Phase 1
-
Examining the Effects of Theta Burst TMS on Brain Connectivity and Balance Ability in Older Adults With Balance Problems
RECRUITING · Early Phase 1
-
Transient Receptor Potential Channels
RECRUITING · Early Phase 1
-
Early Neurovascular Adaptations in Aging Women
RECRUITING · Early Phase 1
-
Heat, Microvascular Function and Aging
RECRUITING · Early Phase 1
-
Angiotensin-(1-7) Cardiovascular Effects in Aging
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.